| 引用本文: | 杜彪,张杰,谢星星,周春阳,杜扬.马来酸依那普利叶酸片治疗H型高血压的系统评价[J].中国现代应用药学,2015,32(12):1488-1493. |
| DU Biao,ZHANG Jie,XIE Xingxing,ZHOU Chunyang,DU Yang.Systematic Review of Enalapril-folic Acid Tablet in Treatment of H-type Hypertension[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(12):1488-1493. |
|
| 摘要: |
| 目的 系统评价马来酸依那普利叶酸片治疗H型高血压的临床疗效和安全性。方法 计算机检索CNKI、维普、万方、PubMed、Medline、EMbase和相关数据库，辅以文献追溯、网上查询等方法，检索建库至2015年5月31日国内外公开发表的马来酸依那普利叶酸片治疗H型高血压随机对照研究，采用RevMan 5.0软件进行定量综合分析。结果 共纳入17篇对照研究，合计H型高血压患者2 323例。其中14项研究介绍了SBP改变情况，结果显示：WMD=-6.73，95%CI：-10.13~-3.39，Z=3.93，P<0.05；14项研究介绍了DBP改变情况，结果显示：WMD=-6.76，95%CI：-10.23~-2.51，Z=5.96，P<0.05；17项研究介绍了Hcy改变情况，结果显示：WMD=-4.18，95%CI：-6.58~-3.03，Z=5.32，P<0.05；7项研究介绍了心脑血管事件发生情况，结果显示：OR=0.28，95%CI：0.18~0.43，Z=5.96，P<0.05。常见不良反应无显著性差异。结论 马来酸依那普利叶酸片治疗H型高血压的疗效和安全性优于马来酸依那普利。 |
| 关键词: 高血压 马来酸依那普利 马来酸依那普利叶酸片 同型半胱氨酸 系统评价 |
| DOI： |
| 分类号: |
| 基金项目:重庆市万州区科技计划资助项目(201403055) |
|
| Systematic Review of Enalapril-folic Acid Tablet in Treatment of H-type Hypertension |
|
DU Biao1, ZHANG Jie2, XIE Xingxing3, ZHOU Chunyang2, DU Yang4
|
|
1.Chongqing Three Gorges Central Hospital, Chongqing 404000, China;2.North Sichuan Medical College, Nanchong 637000, China;3.Sichuan Medical University, Luzhou 646000, China;4.Chongqing Medical University, Chongqing 400016, China
|
| Abstract: |
| OBJECTIVE To evaluate the clinical efficacy and safety of enalapril-folic acid in the treatment of H-type hypertension. METHODS Retrieved from CNKI, VIP, Wanfang database, PubMed, Medline and EMBase, RCTs about Enalapril-folie acid treatment of H-type hypertension were collected and evaluated by Cochrane systematic review. Meta-analysis was carried out by using RevMan 5.0 software. RESULTS The 17 studies were included, involving 2 323 patients. Meta-analysis showed that there was statistical significant between enalapril-folic acid and enalapril on SBP(WMD=-6.73, 95%CI: -10.13- -3.39, Z=3.93, P<0.05), DBP(WMD=-6.76, 95%CI: -10.23- -2.51, Z=5.96, P<0.05) and Hcy(WMD=-4.18, 95%CI: -6.58- -3.03, Z=5.32, P<0.05). The incidence of cardiovascular events in both group had significant difference (OR=0.28, 95%CI: 0.18-0.43, Z=5.96, P<0.05) and the common adverse reactions had no significant difference. CONCLUSION Enalapril-folic acid is more effective and safety than enalapril for treatment of H-type hypertension. |
| Key words: hypertension enalapril enalapril-folic acid tablet homocysteine systematic review |
